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Abstract
The food enzyme considered in this opinion is an endo-1,4-b-xylanase (EC 3.2.1.8) produced with a
genetically modiﬁed strain of Aspergillus niger. The genetic modiﬁcations do not give rise to safety
concerns. The food enzyme contains neither the production organism nor recombinant DNA. The
endo-1,4-b-xylanase is intended to be used in baking processes. Based on the maximum use levels
recommended for the respective food process, dietary exposure to the food enzyme–total organic
solids (TOS) was estimated on the basis of individual data from the EFSA Comprehensive European
Food Consumption Database. This exposure estimate is below 0.013 mg TOS/kg body weight (bw) per
day in European populations. No safety concerns were identiﬁed in relation to the genetic
modiﬁcations performed, the manufacturing process, the compositional and biochemical data provided,
allergenicity and exposure assessments. The allergenicity was evaluated by comparing the amino acid
sequence to those of known allergens; no match was found. The Panel considered that the likelihood
of allergic reactions to dietary intake of endo-1,4-b-xylanase is low and, therefore, does not give rise
to safety concerns. The systemic toxicity was assessed by means of a repeated dose 90-day oral
toxicity study in rodents. A no observed adverse effect level was derived (4,095 and 4,457 mg TOS/kg
bw per day for males and females, respectively), which, compared with the dietary exposure, results in
a sufﬁciently high margin of exposure. However, the genotoxicity data were incomplete. Due to the
absence of the recommended combination of microbial strains used in the Ames test (i.e. lack of
Salmonella Typhimurium TA102 and Escherichia coli WP2), no conclusions can be drawn on potential
DNA oxidising or cross-linking mechanisms giving rise to gene mutations. Consequently, no ﬁnal
conclusions can be drawn on genotoxicity.
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1. Introduction
Article 3 of the Regulation (EC) No 1332/20081 provides deﬁnitions for ‘food enzyme’ and ‘food
enzyme preparation’.
‘Food enzyme’ means a product obtained from plants, animals or microorganisms or products
thereof including a product obtained by a fermentation process using microorganisms: (i) containing
one or more enzymes capable of catalysing a speciﬁc biochemical reaction; and (ii) added to food for a
technological purpose at any stage of the manufacturing, processing, preparation, treatment,
packaging, transport or storage of foods.
‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which
substances such as food additives and/or other food ingredients are incorporated to facilitate their
storage, sale, standardisation, dilution or dissolution.
Before January 2009, food enzymes other than those used as food additives were not regulated or
were regulated as processing aids under the legislation of the Member States. On 20 January 2009,
Regulation (EC) No 1332/2008 on food enzymes entered into force. This Regulation applies to
enzymes that are added to food to perform a technological function in the manufacture, processing,
preparation, treatment, packaging, transport or storage of such food, including enzymes used as
processing aids. Regulation (EC) No 1331/20082 established European Union (EU) procedures for the
safety assessment and the authorisation procedure of food additives, food enzymes and food
ﬂavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:
i) it does not pose a safety concern to the health of the consumer at the level of use proposed;
ii) there is a reasonable technological need;
iii) its use does not mislead the consumer.
All food enzymes currently on the EU market and intended to remain on that market as well as all
new food enzymes shall be subjected to a safety evaluation by the European Food Safety Authority
(EFSA) and an approval via a Union list.
The Guidance on submission of a dossier on a food enzyme for evaluation (EFSA, 2009b) lays down
the administrative, technical and toxicological data required.
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background as provided by the European Commission
Only food enzymes included in the Union list may be placed on the market as such and used in
foods, in accordance with the speciﬁcations and conditions of use provided for in Article 7 (2) of
Regulation (EC) No 1332/2008 on food enzymes. According to Regulation (EC) No 1332/2008 on food
enzymes, a food enzyme which falls within the scope of Regulation (EC) No 1829/20033 on genetically
modiﬁed food and feed should be authorised in accordance with that Regulation as well as under this
Regulation.
An application has been submitted by the company DSM Food Specialities for the authorisation
of the food enzyme endo-1,4-b-xylanase from a genetically modiﬁed strain of Aspergillus niger
(strain XYL).
Following the requirements of Article 12.1 of Commission Regulation (EU) No 234/20114
implementing Regulation (EC) No 1331/2008, the Commission has veriﬁed that the application falls
within the scope of the food enzyme Regulation and contains all the elements required under Chapter
II of that Regulation.
1 Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and
Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/199, Directive 2000/13/EC, Council Directive
2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7–15.
2 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common
authorisation procedure for food additives, food enzymes and food ﬂavourings. OJ L 354, 31.12.2008, p. 1–6.
3 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003 p. 1–23.
4 Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European
Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food
ﬂavourings. OJ L 64, 11.3.2011, p. 15–24.
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1.1.2. Terms of Reference
The European Commission requests EFSA to carry out the safety assessment on the food enzyme
endo-1,4-b-xylanase from a genetically modiﬁed strain of Aspergillus niger (strain XYL) in accordance
with Article 17.3 of Regulation (EC) No 1332/2008 on food enzymes.
1.2. Information on existing authorisations and evaluations
The applicant reports that the Australian/New Zealand, Brazilian, Canadian, Chinese, Danish,
French, Russian and Singaporean authorities have evaluated and authorised the use of endo-1,
4-ß-xylanase from genetically modiﬁed Aspergillus niger in baking processes. The Danish authority also
sets out the conditions of use, including the dosages for speciﬁc foods, which is up to 248
endo-xylanase units (EDX)/kg ﬂour.
2. Data and methodologies
2.1. Data
The applicant has submitted a dossier supporting the application for authorisation of the food
enzyme endo-1,4-b-xylanase obtained from a genetically modiﬁed microorganism and also in the
Abbreviations respectively. (GMM) Aspergillus niger (strain XYL). The food enzyme is intended to be
used in baking processes.
2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA Guidance on
transparency in the scientiﬁc aspects of risk assessment (EFSA, 2009a) and following the relevant
existing Guidances from the EFSA Scientiﬁc Committee.
The current ‘Guidance on the submission of a dossier for safety evaluation of a food enzyme’
(EFSA, 2009b) has been followed for the evaluation of this application with the exception of the
exposure assessment, which was carried out in accordance to the methodology described in the CEF
Panel statement on the exposure assessment of food enzymes (EFSA CEF Panel, 2016).
3. Assessment
3.1. Technical data
3.1.1. Identity of the food enzyme
IUBMB nomenclature: Endo-1,4-b-xylanase
Systematic name: 4-b-D-Xylan xylanohydrolase
Synonyms: Xylanase; endo-1,4-D-b-xylanase
IUBMB No: EC 3.2.1.8
CAS No: 9025-57-4
EINECS No: 232-800-2.
3.1.2. Chemical parameters
The endo-1,4-b-xylanase produced with the genetically modiﬁed Aspergillus niger strain XYL is a
single polypeptide chain of 211 amino acids, including a signal sequence of 27 amino acids. The
molecular mass of the mature protein, with the signal sequence cleaved off, derived from the amino
acid sequence, was calculated to be about 20 kDa. The protein homogeneity status of the food
enzyme was investigated by sodium dodecyl sulfate-poly acrylamide gel electrophoresis (SDS-PAGE)
analysis. The apparent molecular mass based on this technique is about 22 kDa. The protein proﬁle
also included bands corresponding to 116 kDa, 66 kDa and 55 kDa.
Data on the chemical parameters of the food enzyme have been provided for four food enzyme
batches, three batches to be used for commercialisation and one batch used for the toxicological tests
(Table 1).
The total organic solids (TOS) content is a calculated value derived as 100% minus % water minus
% ash. The average TOS content of the three commercial enzyme batches was 23.5% (w/w); the
values ranged from 21.1% to 26.1% (Table 1). The four food enzyme batches presented in Table 1
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are concentrates without any added diluents. The batch used for toxicological tests was spray-dried
after concentration. Consequently, the water content in the latter batch was lower.
The average enzyme activity/TOS ratio of the three commercial food enzyme batches was 212
EDX/mg TOS; the values ranged from 207 to 220 EDX/mg TOS (Table 1). Considering the low
variability of the enzyme activity/TOS ratio in the three commercial food enzyme batches, the average
activity/TOS ratio of 212 EDX/mg TOS was used for subsequent calculations.
Other arabinoxylan-degrading enzymes (xylan-1,4-b-xylosidase and a-L-arabinofuranosidase), which
play a subsidiary role in the application, are known to be present in the food enzyme. No other
enzymatic side activities have been reported by the applicant.
The food enzyme complies with the speciﬁcation for lead (< 5 mg/kg) as laid down in the general
speciﬁcations and considerations for enzymes used in food processing (FAO/WHO, 2006).
The presence of mycotoxins (aﬂatoxins (B1, B2, G1 and G2), ochratoxin A, fumonisins (B1, B2
and B3), nivalenol (NIV), 3-acetyl-deoxynivalenol (3AcDON), 15-acetyl-deoxynivalenol (15AcDON),
fusarenone, T-2 toxin, zearalenone, deoxynivalenol (DON), HT2 toxin (HT2), diacetoxyscirpenol (DAS)
and neosolaniol (NEO)) was examined in the four food enzyme batches and these mycotoxins were found
not to be present at detectable levels in the food enzyme.
The food enzyme complies with the microbiological criteria as laid down in the general
speciﬁcations and considerations for enzymes used in food processing (FAO/WHO, 2006), which
stipulate that Escherichia coli and Salmonella species are absent in 25 g of sample and total coliforms
are not more than 30 colony forming units (CFU) per gram.
The applicant has provided information on the identity of the antifoam agent used. Taking into
account the nature and properties of the antifoam agent, the manufacturing process and the quality
assurance system implemented by the applicant, the Panel considers its use as of no safety concern.
The data provided regarding compositional batch-to-batch-variability are considered sufﬁcient.
Table 1 shows that the food enzyme batch used for the toxicological assays has a lower activity/TOS
ratio and higher ash concentration compared with the three commercial food enzyme batches.
Consequently, this food enzyme batch is cruder than the three commercial food enzyme batches used
and is therefore considered suitable for the toxicological testing.
The Panel considered the compositional data provided for the food enzyme as sufﬁcient.
3.1.3. Properties of the food enzyme
Endo-1,4-b-xylanase catalyses the hydrolysis of 1,4-b-D-xylose linkages in xylan (including
arabinoxylans, i.e. xylan branched with arabinose), resulting in the generation of (1?4)-b-D-xylan
oligosaccharides of different chain lengths. The endo-1,4-b-xylanase of A. niger strain XYL does not
require cofactors.
The endo-1,4-b-xylanase activity is quantiﬁed based on the hydrolysis of arabinoxylan and is
expressed in Endo-Xylanase units/g (EDX/g). The enzyme activity is measured relative to an internal
enzyme standard. The analytical principle is based on the hydrolysis of the substrate arabinoxylan,
resulting in a decrease of the viscosity at 47°C and pH 2.75. One EDX unit is deﬁned as the enzyme
activity that creates a certain viscosity change in one millilitre of the reaction mixture under the
conditions of the assay.
Table 1: Compositional data of the food enzyme
Parameter Unit
Batches
1 2 3 4(a)
Endo-1,4-b-xylanase activity EDX/g batch(b) 57,550 47,965 44,050 143,000
Protein % 19.4 17.7 17.2 76.2
Ash % 0.7 0.4 0.5 2.0
Water % 73.2 76.4 78.4 3.4
Total organic solids (TOS)(c) % 26.1 23.2 21.1 94.6
Endo-1,4-b-xylanase activity/mg TOS EDX/mg TOS 220 207 209 151
(a): Batch used for the toxicological tests. At the time, the tox-batch was produced, the activity was expressed in so-called EXU
units. The activity of the batch 4 was 937,500 EXU/g, corresponding to 143,000 EDX/g.
(b): EDX: Endo-Xylanase units (see Section 3.1.3).
(c): TOS calculated as 100%-% water-% ash.
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Endo-1,4-b-xylanase has been characterised regarding its activity depending on temperature and
pH. The temperature proﬁle has been measured from 0 up to 75°C and the xylanase. The xylanase
shows the temperature optimum of 60°C. The food enzyme is rapidly inactivated at temperatures
above 60°C during baking. The pH proﬁle has been measured within a pH range of 1.5–8.5 (with an
optimum of pH 3).
3.1.4. Information on the source material
3.1.4.1. Information related to the genetically modiﬁed microorganism
According to the CEF Guidance, the certiﬁcate of deposit of the strain in a public validated culture
collection should be provided. The applicant deposited the endo-1,4-b-xylanase production strain
Aspergillus niger XYL only in the DSM internal culture collection under code DS 26538. The
Panel noted that this would not allow a veriﬁcation of the strain independently of the company.
The production strain was taxonomically identiﬁed based on morphology by the Centraalbureau
voor Schimmelcultures (CBS, Utrecht, The Netherlands). The taxonomic identiﬁcation is supported by
whole genome sequence (see Section 3.1.4.2).
3.1.4.2. Characteristics of the recipient or parental microorganisms
The parental microorganism is a ﬁlamentous fungus A. niger. A. niger has a long history of use in the
production of food enzymes (Schuster et al., 2002; van Dijck et al., 2003). A. niger strains are not qualiﬁed
for Qualiﬁed Presumption of Safety (QPS) status because of the potential of toxin production (EFSA
BIOHAZ Panel, 2017). The mycotoxins of concern are ochratoxin A (OTA) and fumonisins (FUM) (Frisvad
et al., 2007); Pel et al. 2007.
). Genome sequence of the ﬁrst intermediate strain (CBS
513.88 = DS 02975), derived from NRRL 3122 by classical mutagenesis and selection, is published,
including discussion on the phylogenetic relationship and synteny between aspergilli (Pel et al. 2007;
Andersen et al. 2011). The recipient strain DS 03043 (also known as GAM-53), derived from DS 02975
by classical mutagenesis and selection contains seven copies of the glucoamylase-encoding glaA gene.
3.1.4.3. Characteristics of the donor organisms
).
3.1.4.4. Description of the genetic modiﬁcation process
3.1.4.5. Safety aspects of the genetic modiﬁcations
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3.1.5. Manufacturing process
The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/20045
and in accordance with current Good Manufacturing Practice (GMP). The manufacturing process is
certiﬁed according to Food Safety Systems Certiﬁcation 22000 (FSSC 22000).
The food enzyme is produced by a pure culture in a contained, submerged, fed-batch fermentation
system with conventional process controls in place. The identity and purity of the culture are checked
at each transfer step from frozen vials until the end of fermentation.
The downstream processing includes recovery, puriﬁcation and concentration. The food enzyme
produced is recovered from the fermentation broth after biomass separation using ﬁltration. Further
puriﬁcation and concentration involve a series of ﬁltration steps, including ultraﬁltration and sterile
ﬁltration.
The Panel considered the information provided on the raw materials and the manufacturing process
as sufﬁcient.
3.1.6. Safety for the environment
Accordingly, as the food enzyme belongs to Category 2 of the guidance on risk assessment of
genetically modiﬁed microorganisms and their products (EFSA GMO Panel, 2011), environmental
exposure to the genetically modiﬁed microorganism is negligible and hence no environmental risk
assessment is required.
3.1.7. Reaction and fate in food
The enzyme endo-1,4-b-xylanase catalyses the hydrolysis of 1,4-b-D-xylosidic linkages in xylan
(including arabinoxylan, i.e. xylan branched with arabinose) resulting in the production of (1?4)-b-D-
xylan and (1?4)-b-D-arabinoxylan oligosaccharides of different lengths.
Endo-1,4-b-xylanase is speciﬁc in its action, not known to catalyse other reactions than this endo-
hydrolysis of xylans to shorter xylan chains, xylo-oligosaccharides and xylose. These reaction products
are naturally present in xylan-containing foods. Owing to the substrate speciﬁcity of the xylanase, no
unintended reaction products in foods are to be expected.
The food enzyme has not been tested for other enzyme activities, however and according to the
applicant it contains side activities such as xylan-1,4-b-xylosidase and a-L-arabinofuranosidase that are
not relevant for food applications.
Therefore, no unintended products resulting from the food enzyme are to be expected.
The data and information provided indicate that the endo-1,4-b-xylanase is inactivated during
processing under the intended conditions of use.
3.1.8. Case of need and intended conditions of use
The endo-1,4-b-xylanase is intended to be used in baking processes6 at a recommended use level
of 0.16–1.17 mg TOS/kg ﬂour.
In baking processes, endo-1,4-b-xylanase is used to facilitate handling of the dough, to improve its
structure and behaviour during baking as well as to reduce batter viscosity. The food enzyme is added
during the preparation of the dough at the beginning of this process.
5 Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food additives.
OJ L 226, 25.6.2004, p. 3–21.
6 The description provided by the applicant has been harmonised by EFSA according to the ‘EC working document describing the
food processes in which food enzymes are intended to be used’ – not yet published at the adoption of this opinion.
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According to the applicant, the food enzyme is used at the minimum dosage necessary to achieve
the desired reaction in line with GMP. The use level applied by a food manufacturer in practice
depends on the particular process.
3.2. Dietary exposure
Exposure estimates were calculated using the methodology described in the CEF Panel statement
on the exposure assessment of food enzymes (EFSA CEF Panel, 2016). The assessment of the food
processes covered in this opinion involved selection of relevant food groups and application of process
and technical conversion factors (Appendix B). These input data were subject to a stakeholder
consultation through open calls,7 and adjusted in accordance with feedback received.
3.2.1. EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (hereafter the EFSA
Comprehensive Database8) has been populated with detailed national data on food consumption.
Competent authorities in European countries provide EFSA with data regarding the level of food
consumption by individual consumers, as taken from the most recent national dietary survey in their
country (EFSA, 2011a). New consumption surveys recently added to the Comprehensive Database
were also taken into account in this assessment.
The food consumption data gathered by EFSA were collected using different methodologies and
thus direct country-to-country comparisons should be interpreted with caution. Depending on the food
category and the level of detail used in exposure calculations, uncertainties might be introduced owing
to possible subjects’ underreporting and/or misreporting of consumption amounts. Nevertheless, the
EFSA Comprehensive Database represents the best available source of food consumption data across
Europe.
Food consumption data from the following population groups: infants, toddlers, children,
adolescents, adults and the elderly were used for the exposure assessment. For the present
assessment, food consumption data were available from 33 different dietary surveys carried out in 19
European countries (Appendix A).
Consumption records were codiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
3.2.2. Exposure assessment methodology
Chronic exposure was calculated based on individual consumption from the Comprehensive
Database, averaged over the total survey period, excluding surveys with only 1 day per subject. High-
level exposure/intake was calculated for only those population groups in which the sample size was
sufﬁciently large to allow calculation of the 95th percentile (EFSA, 2011a).
The exposure per FoodEx category was subsequently added to derive an individual total exposure
per day. Finally, these exposure estimates were averaged over the number of survey days and
normalised for individual body weight (bw), resulting in an individual average exposure/day per kg bw
for the survey period. This was done for all individuals in the survey and per age class, resulting in
distributions of individual average exposure per survey and age class. Based on these distributions, the
mean and 95th percentile exposures were calculated per survey for the total population and per age
class.
3.2.3. Exposure to food enzyme–TOS according to the intended use proposed by
the applicant
Exposure to the food enzyme–TOS was based on intended use and the recommended maximum
use levels of the food enzyme–TOS provided by the applicant (Table 2). Food enzyme–TOS exposure
was calculated from foods produced involving a baking process.
Relevant food groups and/or individual foods were selected from the Comprehensive Database and
were assumed to always contain the food enzyme–TOS at the maximum recommended use level. This
will result in an overestimation of exposure to food enzyme–TOS.
To facilitate matching of the reported use levels for baking processes with foods identiﬁed in the
Comprehensive Database, the selected foods were disaggregated to ingredient level as appropriate,
7 http://www.efsa.europa.eu/en/data/call/161110
8 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
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and converted into the corresponding raw material, i.e. ﬂour, via the application of conversion factors
(Appendix B). For example, consumption of 100 g of bread was converted into an intake of 70 g ﬂour
(recipe fraction of 0.7) and then multiplied by 1.17 mg TOS/kg ﬂour, as provided by the applicant, to
arrive at an exposure of 0.08 mg TOS/100 g bread.
Exposure to the food enzyme–TOS was calculated by multiplying values reported for each food
category by their respective consumption amount per kilogram of body weight (kg bw) separately for
each individual in the database. Table 2 provides an overview of the derived exposure estimates. The
average and 95th percentile exposure to the food enzyme–TOS per age class, country and survey are
reported in Appendix C – Table 1. The contribution of the food enzyme–TOS from each FoodEx
category to the total dietary exposure is indicated in Appendix C – Table 2.
3.2.4. Uncertainty analysis
Uncertainties in the exposure assessment of the food enzyme have been discussed above. In
accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary exposure
assessment (EFSA, 2007), the following sources of uncertainties have been considered and are
summarised in Table 3.
Table 2: Summary of estimated dietary exposure to food enzyme–TOS in six population groups
Estimated
exposure
(mg/kg bw
per day)
Infants Toddlers Children Adolescents Adults The elderly
Age range 3–11 months 12–35 months 3–9 years 10–17 years 18–64 years ≥ 65 years
Min–max mean
(number of
surveys)
0.000–0.004 (6) 0.003–0.007 (10) 0.003–0.007 (18) 0.002–0.005 (17) 0.001–0.003 (17) 0.001–0.002 (14)
Min–max 95th
percentile
(number of
surveys)
0.004–0.010 (5) 0.007–0.012 (7) 0.006–0.013 (18) 0.003–0.009 (17) 0.003–0.006 (17) 0.002–0.004 (14)
bw: body weight.
Table 3: Qualitative evaluation of the inﬂuence of uncertainties on the dietary exposure estimate
Sources of uncertainties
Direction of impact
Exposure to food
enzyme–TOS
Model input data
Consumption data: different methodologies/representativeness/underreporting/
misreporting/no portion size standard
+/
Use of data from food consumption survey of a few days to estimate long-term
(chronic) exposure for high percentiles (95th percentile)
+
Possible national differences in categorisation and classiﬁcation of food +/
Model assumptions and factors
FoodEx categories included in the exposure assessment were assumed to always
contain the food enzyme–TOS
+
Exposure to food enzyme–TOS was always calculated based on the recommended
maximum use level
+
Selection of broad FoodEx categories for the exposure assessment based on the
description of the food process provided by the applicant (based on examples given
by applicant)
+
Use of recipe fractions in disaggregation FoodEx categories likely to contain the food
enzyme
+/
+: uncertainty with potential to cause overestimation of exposure; : uncertainty with potential to cause underestimation of
exposure.
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The conservative approach applied to the exposure estimate to food enzyme–TOS, in particular,
assumptions made on the occurrence and use levels of this speciﬁc food enzyme, is likely to have led
to a considerable overestimation of the exposure.
3.3. Toxicological data
The toxicological assays were performed with the tox-batch which was produced according to the
procedure used for commercial production. It was spray-dried after ultraﬁltration (UF) concentration
and the test material became more concentrated.
3.3.1. Bacterial reverse mutation test
In order to investigate the potential to induce gene mutations in bacteria, a bacterial reverse
mutation assay (Ames test) was performed according to OECD Test Guideline 471 (OECD, 1983) and
following Good Laboratory Practice (GLP) strains of Salmonella Typhimurium (TA98, TA100, TA1535
and TA1537) in the presence or absence of metabolic activation (S9-mix) applying the ‘treat and plate
assay’. The food enzyme was not tested in S. Typhimurium TA102 or E. coli WP2 strains. Two
independent experiments were carried out using ﬁve different concentrations of the food enzyme
(100, 320, 1,000, 3,200 and 10,000 lg food enzyme/ml, corresponding to ca. 95, 303, 946, 3,027 and
9,460 lg TOS/ml), positive controls and puriﬁed water as negative control.
Neither a certiﬁcate on quality control and production for the post-mitochondrial fraction nor a
statement clarifying whether each batch has been characterized with a mutagen that requires
metabolic activation by microsomal enzymes, were provided. All positive controls induced signiﬁcant
increases in revertant colony numbers, while the negative controls were within the normal ranges.
Upon treatment with the food enzyme, there was no increase in revertant colony numbers above
control values in any strain either with or without metabolic activation. The Panel concluded that the
food enzyme did not induce gene mutations in the four strains tested. However, based on literature
(Wilcox et al., 1990) and on the most recent version of OECD Guideline No. 471 (OECD, 1997) these
four S. Typhimurium strains may not detect certain oxidising mutagens, cross-linking agents and
hydrazines. Such substances may be detected by E. coli WP2 strains or S. Typhimurium TA102. The
applicant was requested, but declined to provide these data. Therefore, no conclusions can be drawn
on the possibility of the food enzyme to induce gene mutations by DNA oxidising or cross-linking
mechanisms.
3.3.2. In vitro mammalian chromosomal aberration test
The in vitro mammalian chromosome aberration test was carried out according to the OECD Test
Guideline 473 (OECD, 1983) and following GLP. Human peripheral whole blood cultures were treated
with physiological saline (negative control), the food enzyme or positive controls (chlorambucil and
cyclophosphamide, in the absence and presence of S9-mix, respectively). Two experiments were
performed in duplicate cultures. In the absence of S9-mix, the cells were exposed continuously to the
food enzyme for 21 h (1,250, 2,500 and 5,000 lg/mL, corresponding to ca 1,183, 2,365 and 4,730 lg
TOS/mL) and 45 h (5,000 lg/mL corresponding to ca 4,730 lg TOS/mL). In the presence of S9-mix,
the cultures were exposed to the food enzyme for 3 h and harvested after 18 or 42 h of recovery
(1,250, 2,500 and 5,000 lg/mL corresponding to ca 1,183, 2,365 and 4,730 lg TOS/mL). Two
hundred metaphases were scored per experimental point. The reductions in mitotic index did not
exceed 41% of negative control values at any concentration of food enzyme tested. The frequency of
chromosomal aberrations in treated cultures was comparable to the values detected in negative
controls. No signiﬁcant increase in polyploid or endoreplicated cells was observed. Based on the
biological relevance of the results, it was concluded that the food enzyme did not induce structural
chromosome aberrations in cultured mammalian cells when tested up to 5,000 lg food enzyme/mL
(corresponding to ca 4,730 lg TOS/mL) under the conditions of the study.
3.3.3. Repeated dose 90-day oral toxicity study in rodents
The repeated dose 90-day oral toxicity study was performed in accordance with OECD Test
Guideline 408 (OECD, 1981) and following GLP. Groups of 10 male and 10 female CD strain rats,
4–5 weeks old, received the food enzyme as a powder mixed with their RM1 diet for 13 weeks at low-,
mid- and high-dose levels of 2,000, 10,000 and 50,000 mg food enzyme/kg diet equivalent to 1,892,
9,460 and 47,300 mg TOS/kg diet. Average consumptions of food enzyme corresponded to 162, 811
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and 4,095 mg TOS/kg bw per day for males and 171, 855 and 4,457 mg TOS/kg bw per day for
females, respectively. Control groups received RM1 diet alone.
No treatment-related deaths or clinical signs or consistent effects on body weight, food
consumption, food conversion efﬁciency, ophthalmic lesions or haematological parameters were
observed. During week 13 of treatment, prothrombin time was marginally higher for all treated females
(13.8  0.8, 13.3  0.6 and 13.2  0.9 s for low, mid and high dose, respectively) in comparison to
the control group (12.4  0.6 s). However, these were within the range of the laboratory historical
control data (13.9  1.2 s for 744 animals) and no pathological or liver enzyme changes were
observed.
Marginal, but statistically signiﬁcant increases of urinary total protein and alpha-1-globulin levels
observed in high-dose females were considered of no toxicological relevance.
Although increases of the absolute and relative weights of the adrenal glands (16% and 17%,
respectively) and ovary (21% and 22%, respectively) were seen in the female group at the highest
dose, histopathological examination showed no evidence of any changes related to treatment.
Overall, the Panel derived a no observed adverse effect level (NOAEL) based on the high dose level
of 4,095 mg TOS/kg bw per day for males and 4,457 mg TOS/kg bw per day for females, respectively.
A comparison of the NOAEL (4,457 mg TOS/kg bw per day) from the 90-day study with the derived
exposure estimates of 0.001–0.007 mg/kg bw per day at the mean and from 0.002–0.013 mg TOS/kg
bw per day at the 95th percentile, resulted in margin of exposures (MOEs) above 3 x 105, indicating
that there is no safety concern.
3.4. Allergenicity
The potential allergenicity of the endo-1,4-b-xylanase (xylanase) from the genetically modiﬁed
A. niger (strain XYL) has been assessed by comparison of its amino acid sequence with those of
known allergens according to the EFSA Scientiﬁc opinion on the assessment of allergenicity of
genetically modiﬁed plants and microorganisms and derived food and feed of the Scientiﬁc Panel on
Genetically Modiﬁed Organisms (EFSA GMO Panel, 2010). Using higher than 35% identity in a sliding
window of 80 amino acids as criterion, no match was found.
Several cases of occupational allergy consecutive to inhalation of aerosols containing xylanase or
other enzymes have been reported (Martel et al., 2010). However, several studies have shown that
adults with occupational asthma can ingest respiratory allergens without acquiring clinical symptoms of
food allergy (Brisman, 2002; Poulsen, 2004; Armentia et al., 2009). In addition, no food allergic
reactions to xylanase have been reported in the literature.
Xylanase from a genetically modiﬁed Aspergillus oryzae was also tested in the study of Bindslev-
Jensen et al. (2006) to investigate the possible cross-reactivity of 19 different commercial enzymes used
in the food industry in allergic patients (400 patients allergic to inhalation allergens, food allergens, bee or
wasp). In a few patients, the tested xylanase from a genetically modiﬁed A. oryzae gave positive results
in a skin prick test and a histamine release test; however, these positive reactions are without clinical
relevance as oral exposure to even high doses of the xylanase did not result in allergic reactions.
Consequently, the CEF Panel considers that the likelihood of food allergic reactions to this endo-1,
4-b-xylanase produced with the genetically modiﬁed strain of A. niger (strain XYL) is low and therefore
does not raise safety concerns.
Conclusions
No safety concerns were identiﬁed in relation to the genetic modiﬁcations performed, the
manufacturing process, the compositional and biochemical data provided, allergenicity and exposure
assessments. Regarding the toxicological studies, the repeated dose oral 90-day study also did not
raise safety concerns. However, in the absence of the recommended combination of microbial strains
used in the Ames test, no conclusions can be drawn on a DNA oxidising or cross-linking potential.
Consequently, no ﬁnal conclusion can be drawn on genotoxicity.
Documentation provided to EFSA
1) Dossier ‘Application for authorisation of xylanase derived from a genetically modiﬁed strain of
Aspergillus niger (strain XYL)’. November 2014. Submitted by DSM Food Specialities.
2) Additional information submitted on 17 June 2015 by the applicant.
3) Additional information submitted on 26 October 2016 by the applicant.
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4) Summary report on GMM part for xylanase derived from a genetically modiﬁed strain of
Aspergillus niger (strain XYL), EFSA-Q-2014-00305’. Delivered by Technical University of
Denmark (DTU).
5) Summary report on technical data and dietary exposure for xylanase derived from a
genetically modiﬁed strain of Aspergillus niger (strain XYL). Delivered by Hylobates
Consulting (Rome, Italy) and BiCT (Lodi, Italy).
6) Summary report on genotoxicity and subchronic toxicity study related to endo-1,4-beta-
xylanase produced with a strain of Aspergillus niger (strain XYL). Delivered by FoBiG GmbH,
(Freiburg, Germany).
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Abbreviations
3AcDON 3-acetyl-deoxynivalenol
15AcDON 15-acetyl-deoxynivalenol
bw body weight
CAS Chemical Abstracts Service
CBS Centraalbureau voor Schimmelcultures
CEF EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids
CFU colony forming units
DAS diacetoxyscirpenol
DON deoxynivalenol
EC Enzyme Commission
EINECS European Inventory of Existing Commercial Chemical Substances
EDX endo-xylanase units
FAO Food and Agricultural Organization
FSSC Food Safety Systems Certiﬁcation
FUM fumonisin
GLP Good Laboratory Practice
GMM genetically modiﬁed microorganism
GMO genetically modiﬁed organisms
GMP Good Manufacturing Practice
IUBMB International Union of Biochemistry and Molecular Biology
JECFA Joint FAO/WHO Expert Committee on Food Additives
MOE margin of exposure
NEO neosolaniol
NIV nivalenol
NOAEL no observed adverse effect level
OECD Organisation for Economic Cooperation and Development
OTA ochratoxin A
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RNA ribonucleic acid
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
QPS Qualiﬁed Presumption of Safety
TOS total organic solids
UF ultraﬁltration
WHO World Health Organization
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Appendix A – Population groups considered for the exposure assessment
Population Age range
Countries with food consumption surveys covering
more than 1 day
Infants From 12 weeks on up to and
including 11 months of age
Bulgaria, Denmark, Finland, Germany, Italy, United Kingdom
Toddlers From 12 months up to and
including 35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany, Italy,
Netherlands, Spain, United Kingdom
Children(a) From 36 months up to and
including 9 years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark,
Finland, France, Germany, Greece, Italy, Latvia, Netherlands,
Spain, Sweden, United Kingdom
Adolescents From 10 years up to and
including 17 years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland,
France, Germany, Italy, Latvia, Spain, Sweden, United
Kingdom
Adults From 18 years up to and
including 64 years of age
Austria, Belgium, Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Netherlands,
Romania, Spain, Sweden, United Kingdom
The elderly(a) From 65 years of age and older Austria, Belgium, Denmark, Finland, France, Germany,
Hungary, Ireland, Italy, Romania, Sweden, United Kingdom
(a): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
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Appendix B – FoodEx categories used to derive exposure estimates for the
food enzyme–TOS and the respective conversion factors
FoodEx code FoodEx category
Conversion factor
from FoodEx food
group to raw
material
Recipe
fraction
mg
TOS/kg
ﬂour
A.01 Grains and grain-based products (unspeciﬁed) 0.8 1 1.17
A.01.03 Grain milling products (unspeciﬁed) 1 1 1.17
A.01.03.001 Wheat milling products (unspeciﬁed) 1 1 1.17
A.01.03.001.001 Wheat ﬂour, brown 1 1 1.17
A.01.03.001.002 Wheat ﬂour, Durum 1 1 1.17
A.01.03.001.003 Wheat ﬂour, white 1 1 1.17
A.01.03.001.004 Wheat ﬂour, wholemeal 1 1 1.17
A.01.03.001.005 Graham ﬂour 1 1 1.17
A.01.03.001.006 Wheat ﬂour, gluten free 1 1 1.17
A.01.03.001.014 Wheat starch 1.2 1 1.17
A.01.03.002 Rye milling products (unspeciﬁed) 1 1 1.17
A.01.03.002.001 Rye ﬂour, gluten free 1 1 1.17
A.01.03.002.002 Rye ﬂour, light 1 1 1.17
A.01.03.002.003 Rye ﬂour, medium 1 1 1.17
A.01.03.002.004 Rye ﬂour, wholemeal 1 1 1.17
A.01.03.003 Buckwheat milling products (unspeciﬁed) 1 1 1.17
A.01.03.003.001 Buckwheat ﬂour 1 1 1.17
A.01.03.004 Corn milling products (unspeciﬁed) 1 1 1.17
A.01.03.004.001 Corn ﬂour 1 1 1.17
A.01.03.004.003 Corn starch 1.3 1 1.17
A.01.03.005 Oat milling products (unspeciﬁed) 1 1 1.17
A.01.03.005.002 Oat ﬂour 1 1 1.17
A.01.03.005.004 Oat starch 1.2 1 1.17
A.01.03.006 Rice milling products (unspeciﬁed) 1 1 1.17
A.01.03.006.001 Rice ﬂour 1 1 1.17
A.01.03.006.002 Rice ﬂour white 1 1 1.17
A.01.03.006.003 Rice ﬂour, instant 1 1 1.17
A.01.03.006.004 Rice starch 1.2 1 1.17
A.01.03.007 Spelt milling products 1 1 1.17
A.01.03.008 Other milling products (unspeciﬁed) 1 1 1.17
A.01.03.008.001 Amaranth ﬂour 1 1 1.17
A.01.03.008.002 Barley ﬂour 1 1 1.17
A.01.03.008.003 Chapatti ﬂour 1 1 1.17
A.01.03.008.004 Flour mix, wheat/rye/barley/oats 1 1 1.17
A.01.03.008.005 Millet ﬂour 1 1 1.17
A.01.03.008.007 Sorghum ﬂour 1 1 1.17
A.01.04 Bread and rolls (unspeciﬁed) 1 0.7 1.17
A.01.04.001 Wheat bread and rolls 1 0.7 1.17
A.01.04.002 Rye bread and rolls 1 0.7 1.17
A.01.04.003 Mixed wheat and rye bread and rolls 1 0.7 1.17
A.01.04.004 Multigrain bread and rolls 1 0.7 1.17
A.01.04.005 Unleavened bread, crisp bread
and rusk (unspeciﬁed)
1 0.8 1.17
A.01.04.005.001 Crisp bread, rye wholemeal 1 0.9 1.17
A.01.04.005.002 Crisp bread, rye, light 1 0.9 1.17
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FoodEx code FoodEx category
Conversion factor
from FoodEx food
group to raw
material
Recipe
fraction
mg
TOS/kg
ﬂour
A.01.04.005.003 Crisp bread, wheat, wholemeal 1 0.9 1.17
A.01.04.005.004 Crisp bread, wheat, light 1 0.9 1.17
A.01.04.005.005 Rusk, light 1 0.9 1.17
A.01.04.005.006 Rusk, wholemeal 1 0.9 1.17
A.01.04.005.007 Pita bread 1 0.7 1.17
A.01.04.005.008 Matzo 1 0.9 1.17
A.01.04.005.009 Tortilla 1 0.7 1.17
A.01.04.006 Other bread 1 0.7 1.17
A.01.04.007 Bread products 1 0.7 1.17
A.01.07 Fine bakery wares (unspeciﬁed) 1 0.5 1.17
A.01.07.001 Pastries and cakes (unspeciﬁed) 1 0.5 1.17
A.01.07.001.001 Beignets 1 0.15 1.17
A.01.07.001.002 Buns 1 0.7 1.17
A.01.07.001.003 Cake from batter 1 0.25 1.17
A.01.07.001.004 Cheese cream cake 1 0.24 1.17
A.01.07.001.005 Cheese cream sponge cake 1 0.24 1.17
A.01.07.001.006 Chocolate cake 1 0.24 1.17
A.01.07.001.007 Chocolate cake with fruits 1 0.24 1.17
A.01.07.001.008 Cream cake 1 0.24 1.17
A.01.07.001.009 Cream cheese cake 1 0.24 1.17
A.01.07.001.010 Cream custard cake 1 0.24 1.17
A.01.07.001.011 Cream custard sponge cake 1 0.24 1.17
A.01.07.001.012 Croissant 1 0.5 1.17
A.01.07.001.013 Croissant, ﬁlled with chocolate 1 0.5 1.17
A.01.07.001.014 Croissant, ﬁlled with cream 1 0.5 1.17
A.01.07.001.015 Croissant, ﬁlled with jam 1 0.5 1.17
A.01.07.001.016 Croquembouche 1 0.15 1.17
A.01.07.001.017 Doughnuts 1 0.24 1.17
A.01.07.001.018 Clair 1 0.15 1.17
A.01.07.001.019 Flan 1 0.5 1.17
A.01.07.001.020 Fruit cake 1 0.6 1.17
A.01.07.001.021 Fruit pie 1 0.15 1.17
A.01.07.001.022 Cheese pie 1 0.15 1.17
A.01.07.001.023 Fruit tart 1 0.15 1.17
A.01.07.001.024 Gingerbread 1 0.6 1.17
A.01.07.001.025 Gougere 1 0.15 1.17
A.01.07.001.026 Kringles 1 0.25 1.17
A.01.07.001.027 Nut cream cake 1 0.24 1.17
A.01.07.001.028 Pancakes 1 0.25 1.17
A.01.07.001.029 Proﬁterole 1 0.15 1.17
A.01.07.001.030 Pyramid cake 1 0.25 1.17
A.01.07.001.031 Rhubarb ﬂan 1 0.15 1.17
A.01.07.001.032 Scone 1 0.5 1.17
A.01.07.001.033 Sponge dough 1 0.25 1.17
A.01.07.001.034 Sponge cake 1 0.25 1.17
A.01.07.001.035 Sponge cake roll 1 0.25 1.17
A.01.07.001.036 Mufﬁns 1 0.25 1.17
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FoodEx code FoodEx category
Conversion factor
from FoodEx food
group to raw
material
Recipe
fraction
mg
TOS/kg
ﬂour
A.01.07.001.037 Wafﬂes 1 0.25 1.17
A.01.07.001.038 Apple strudel 1 0.15 1.17
A.01.07.001.039 Cream-cheese strudel 1 0.24 1.17
A.01.07.001.040 Cheese pastry goods from puff pastry 1 0.15 1.17
A.01.07.001.041 Croissant from puff pastry 1 0.6 1.17
A.01.07.001.042 Brioche 1 0.5 1.17
A.01.07.001.044 Lebkuchen 1 0.6 1.17
A.01.07.001.045 Dumpling 1 0.5 1.17
A.01.07.001.046 Cake marbled, with chocolate 1 0.5 1.17
A.01.07.001.047 Marzipan pie 1 0.25 1.17
A.01.07.001.048 Baklava 1 0.15 1.17
A.01.07.002 Biscuits (cookies) 1 0.9 1.17
A.01.07.002.001 Biscuits, sweet, plain 1 0.9 1.17
A.01.07.002.002 Biscuits, chocolate ﬁlling 1 0.81 1.17
A.01.07.002.003 Biscuits, cream ﬁlling 1 0.81 1.17
A.01.07.002.004 Biscuits, fruit ﬁlling 1 0.81 1.17
A.01.07.002.005 Biscuits, vanilla ﬁlling 1 0.81 1.17
A.01.07.002.006 Butter biscuits 1 0.81 1.17
A.01.07.002.007 Biscuit, iced 1 0.81 1.17
A.01.07.002.008 Speculaas 1 0.9 1.17
A.01.07.002.009 Biscuits, sweet, wheat wholemeal 1 0.9 1.17
A.01.07.002.010 Biscuits, oat meal 1 0.9 1.17
A.01.07.002.011 Biscuits, spelt meal 1 0.9 1.17
A.01.07.002.012 Biscuits, salty 1 0.9 1.17
A.01.07.002.013 Biscuits, salty, with cheese 1 0.81 1.17
A.01.07.002.014 Sticks, salty 1 0.81 1.17
A.17.03.003 Biscuits, rusks and cookies for children 1 0.9 1.17
A.18.04.001 Find bakery products for diabetics 1 0.5 1.17
A.19.01.002 Pizza and pizza-like pies 1 0.3 1.17
TOS: total organic solids.
(a): Food and Agriculture Organization of the United Nations. Technical Conversion Factors for Agricultural Commodities. Available
from: http://www.fao.org/economic/the-statistics-division-ess/methodology/methodology-systems/technical-conversion-factors-
for-agricultural-commodities/en/
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Appendix C – Dietary exposure estimates to the food enzyme–TOS in
details
Information provided in this appendix is shown in an excel ﬁle (downloadable http://onlinelibrary.
wiley.com/wol1/doi/10.2903/j.efsa.2017.4755/suppinfo).
The ﬁle contains two sheets, corresponding to two tables.
Table 1: Average and 95th percentile exposure to the food enzyme–TOS per age class, country and
survey
Table 2: The contribution of the food enzyme–TOS from each FoodEx category to the total dietary
exposure
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